CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About CADTH What We Do Programs and Services CADTH Reimbursement Review Tocilizumab

Tocilizumab

Last Updated: January 30, 2012

Result type: Reports

Project Number: S0267

Product Line: Reimbursement Review

Generic Name: Tocilizumab

Brand Name: Actemra

Manufacturer: Hoffman-La Roche Ltd.

Therapeutic Area: Arthritis, juvenile idiopathic

Indications: Arthritis, juvenile idiopathic

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: July 19, 2012

Recommendation Type: List with clinical criteria and/or conditions

Tocilizumab

Files